Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

F0778

Sigma-Aldrich

Felbamate

Sinônimo(s):

2-Phenyl-1,3-propanediol dicarbamate

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C11H14N2O4
Número CAS:
25451-15-4
Peso molecular:
238.24
Número CE:
247-001-4
Número MDL:
MFCD00865296
Código UNSPSC:
12352200
ID de substância PubChem:
24277968
NACRES:
NA.77

Nível de qualidade

200

solubilidade

alcohol: soluble

cadeia de caracteres SMILES

NC(=O)OCC(COC(N)=O)c1ccccc1

InChI

1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

chave InChI

WKGXYQFOCVYPAC-UHFFFAOYSA-N

Informações sobre genes

human ... GRIN1(2902) , GRIN2A(2903) , GRIN2B(2904) , GRIN2C(2905) , GRIN2D(2906) , GRIN3A(116443) , GRIN3B(116444)

Procurando produtos similares? Visita Guia de comparação de produtos

Ações bioquímicas/fisiológicas

Anticonvulsant agent that is an allosteric antagonist at the NR2B subunit of the NMDA glutamate receptor; also has γ-aminobutyric acid (GABAA) receptor agonist properties.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
047M4112V
079M4147V
13180111
13170306
096M4045V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

K D Laxer
The Western journal of medicine, 161(3), 309-314 (1994-09-01)
For the first time in 15 years, new antiepileptic medications are available for the treatment of patients with seizure disorders. These drugs have demonstrated efficacy in animal models of epilepsy and in controlled clinical trials. Felbamate was licensed in 1993
John M Pellock et al.
Epilepsy research, 71(2-3), 89-101 (2006-08-08)
An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed
Angelique M Leone et al.
Chemical research in toxicology, 20(4), 600-608 (2007-03-27)
Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man. Idiosyncratic reactions account for over half of toxicity-related drug failures
N W Kleckner et al.
The Journal of pharmacology and experimental therapeutics, 289(2), 886-894 (1999-04-24)
Felbamate is an anticonvulsant used in the treatment of seizures associated with Lennox-Gastaut syndrome and complex partial seizures that are refractory to other medications. Its unique clinical profile is thought to be due to an interaction with N-methyl-D-aspartate (NMDA) receptors
J M Pellock
Epilepsia, 40 Suppl 5, S57-S62 (1999-10-26)
Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy. The identification of
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica